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Abstract
Conjugated linoleic acids (CLA) were identified in 1980’s, since then it has been intensively studied due to its various beneficial health effects
such as anti-inflammatory, anti-atherogenic, anti-carcinogenic and anti-diabetic/obesity effects. Isomer specificity of a number of CLA isomers, especially
predominant isomer 9Z,11E- and 10E,12Z-CLA, is now recognized. However, the less prevalent CLA isomers have not been well characterized. 
Recently, studies have reported the distinctively different effects of 9E,11E-CLA in colon cancer cells, endothelial cells, and macrophage cells compared 
to the rest of CLA isomers. In this review, various effects of CLAs, especially anti-inflammatory and anti-atherogenic effects, will be discussed
with focusing on the isomer-specific effects and potential mechanism of action of CLA. At last, recent studies about 9E,11E-CLA in in vitro and
animal models will be discussed. 
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Overview of conjugated linoleic acids21)
CLAs are fatty acids that are mainly found in foods derived 
from ruminant animals (Pariza & Ha, 1990). They are geometrical 
and positional isomers of its parent molecule, linoleic acid 
(cis-9,cis-12-18:2, n-6 (LA)). The cis-9,  trans-11 (9Z,11E- 
octadecenoic acid, C18:2) isomer, also known as rumenic acid 
(RA), is generated via biohydrogenation of dietary linoleic acids 
by ruminant microflora and is the most abundant natural CLA 
isomer (over 75-80% of total CLA). It is not clear whether 
humans are able to produce RA from other fatty acids (Yurawecz, 
1999); however, it is likely that the majority of RA found in 
the human body originates from the diet. Estimated CLA intake 
for humans is between 0.5 and 1 g/d (Ip et al., 1994); however, 
more recent estimates suggest that CLA and RA intakes are much 
lower (Yurawecz, 1999). For example, the average intake is 430 
mg/day for men and 350 mg/day for women in Germany, 212 
mg/day for men and 151 mg/day for women in the USA, and 
500-1,000 mg/day in Australia (Yurawecz, 1999). 
Studied for its potential beneficial effects of CLA on animal 
health have focused on anti-inflammatory, anti-atherogenic, 
anti-carcinogenic, and anti-diabetic/anti-obesity effects; however, 
the beneficial effects of CLA in humans is inconclusive (Kelly, 
2001; Pariza et al., 2001; Rainer & Heiss, 2004; Wahle et al., 
2004; Whigham et al., 2000). It is important to note that a 
majority of the CLA studies was performed with a chemically 
synthesized CLA mixture, although in recent years, some were 
done with relatively pure 9Z,11E-CLA or 10E,12Z-CLA isomers. 
CLA supplements which predominantly contain two major CLA 
isomers are on the market; however, the safety of CLA is a 
concern in public health. To obtain beneficial amounts of CLA, 
one must ingest 10-200 times what can be achieved in diet 
(Gaullier et al., 2002). Although animal studies on CLA showed 
that it is reasonably safe and well-tolerated in rats, dogs, and 
pigs (O'Hagan & Menzel, 2003; Pariza, 2004; Scimeca, 1998), 
whether the same is true for humans is not known. Gaullier et 
al. (2002) stated that CLA enriched with 9Z,11E- and 
10E,12Z-CLA may be better for human consumption than one 
enriched with 8E,10Z-, 9Z,11E-, 10E,12Z-, and 11Z,13E-CLA. 
In spite of these conclusions, concerns on CLA safety remain 
due to its adverse effects which induce fatty liver, insulin 
resistance, and lipodystrophy in mice and increase C-reactive 
protein levels, lipid peroxidation, and reduction of milk fat in 
humans (Pariza, 2004); therefore, it is essential for long-term 
human studies to make solid conclusions on recommending a 
proper amount of CLA supplementation to the public. It is also 
important to consider differences in CLA isomers in terms of 
both benefits and potential toxicity.
Anti-inflammatory effects
Levels of fatty acids are known to have a great impact on 
immune function. Dietary fat intake directly influences the fatty 
acid profile of blood lipids and cells. The immune-modulating 
effects of saturated and polyunsaturated fatty acids have been 
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reported (Calder & Grimble, 2002). However, the available 
knowledge about the effects of CLAs on immune function in 
animals or humans is limited. The inflammatory-modulating 
effects of CLA are mainly observed in in vitro and animal 
models, while CLA’s anti-inflammatory effects are not conclusive 
in human studies. Chicks and rats fed 0.5% CLA for 4 wks gained 
weight even after LPS injection, whereas chicks and rats without 
CLA lost weight. This led to the idea that CLA inhibited the 
catabolic effects of endotoxin (Cook et al., 1993). CLA fed mice 
had higher levels of IL-2 compared to control diet fed mice 
(Hayek et al., 1999; Wong et al., 1997), while TNF-α and IL-6 
levels were decreased (Rahman et al., 2007). However, Kelley 
et al. (2002) reported that both 9Z,11E- and 10E,12Z-CLA 
significantly and similarly increased TNF-α  and IL-6 levels 
without altering prostaglandin levels in CLA fed mice.
In  in vitro models, CLA was positively related to anti- 
inflammatory effects. For example, Yu et al. (2002) showed that 
CLA reduced TNF-α and IL-6 levels induced by IFN-γ, at least 
partially by a PPARγ-dependent pathway. CLA induced IFN-γ 
and IL-2 levels in Juckat T cells (Luongo et al., 2003). Moreover, 
IL-10 receptor and IL-10 levels were induced by CLA in mouse 
dendritic cells (Loscher et al., 2005). In human epithelial cells, 
9Z,11E-CLA attenuated cell growth and reduced IL-8 levels 
while 10E,12Z-CLA had no effect (Jaudszus et al., 2005).
The results from human studies focusing on anti-inflammatory 
effects of CLA are inconclusive. Song et al. (2005) demonstrated 
that CLA supplementation could be beneficial in humans (3 g/d 
CLA for 12 wks) by enhancing IgA, IgM, and IL-10 but 
inhibiting IgE, TNF-α, and IL-1β. In addition, CLA boosted the 
hepatitis B vaccination in healthy human subjects although it did 
not alter other aspects of immune function including NK cell 
activity, lymphocyte proliferation, and production of TNF-α, IL-1
β, IL-6, IL-2, IL-4, IFN-γ, and PGE2 (Albers et al., 2003). In 
contrast, other human studies showed no significant relationship 
between CLA and anti-inflammatory effect (Albers et al., 2003; 
Kelley et al., 2000; Nugent et al., 2005; Ramakers et al., 2005; 
Ritzenthaler et al., 2005; Tricon et al., 2004a). There were no 
changes on the levels of PGE2, leukotriene B4, IL-1β, and TNF-α 
that were induced by LPS in young healthy women (Kelley et 
al., 2000). 
The regulation of immune functions by CLA does not seem 
to be affected by a single mechanism. CLA affects the production 
of eicosanoids either directly or indirectly, enhances PPARγ 
activation, attenuates the NF-κB pathway, or directly decreases 
pro-inflammatory cytokines to have beneficial effects on 
inflammation which ultimately influence metabolic syndromes 
including obesity, insulin resistance, and atherosclerosis (Zulet 
et al., 2005). CLA decreased the production of eicosanoids such 
as PGE2, PGF2α, and LTB4 (Li & Watkins, 1998; Sugano et 
al., 1998), although the reduction of the eicosanoid production 
was not consistent (Hayek et al., 1999; Kelley et al., 2000). The 
mechanism by which CLA reduces AA-derived eicosanoids can 
be explained as follows: (1) CLA displaces AA in phospholipids; 
(2) CLA competes with LA for desaturation and elongation; (3) 
CLA or CLA metabolites may act as substrates or antagonists 
for enzymes involved in the prostaglandin production process; 
and (4) CLA-derived eicosanoids themselves may have anti- 
inflammatory properties. The PPARγ subtype is highly expressed 
in adipose tissue and macrophages (Olefsky, 2001). Most importantly, 
PPARγ plays a critical role in the regulation of inflammation 
(Cuzzocrea et al., 2004). Various CLA isomers activate PPARγ 
in RAW 264.7 cells and decrease pro-inflammatory cytokines 
induced by IFN-γ (Yu et al., 2002). NF-κB is a transcription 
factor that is involved in  cytokine gene expression, cellular 
adhesion,
  cell cycle activation, apoptosis, and carcinogenesis. 
CLA negatively regulates inflammatory mediators via the NF-κB 
pathway by inhibiting IκB phosphorylation (Cheng et al., 2004). 
Finally, CLA could exert direct anti-inflammatory properties by 
regulating the gene expression of inflammation mediators 
(Loscher et al., 2005; Luongo et al., 2003; Song et al., 2005), 
perhaps due to effects on NF-κB or PPARγ.
In conclusion, the anti-inflammatory action of CLA brings potential 
therapies for diseases such as atherosclerosis, diabetes, cancers, 
rheumatism, inflammatory bowel disease and obesity. Meanwhile, 
the lack of understanding regarding CLAs mechanism (s) of action, 
safety issue surrounding CLA as a dietary supplement, and isomer- 
specific effects on regulating inflammatory mediators require further 
studies. 
Anti-atherogenic effects
Atherosclerosis is a complex disease that is influenced in part 
by inflammation (reviewed in (Ross, 1999)). Interactions between 
lipoproteins, monocyte-derived macrophages, T cells, and the 
normal cellular elements of the arterial wall are important 
contributors for the development of atherosclerosis. CLA-fed 
rabbits had significantly lower low density lipoprotein (LDL) 
cholesterol and TG levels as well as a lower ratio of LDL/HDL 
(high density lipoprotein) and LDL/total cholesterol compared 
to control diet fed rabbits (Kritchevsky et al., 2000; Lee et al., 
1994). In hamsters, CLA reduced total cholesterol, LDL, VLDL 
(very low density lipoprotein), and TG although there were no 
changes on HDL levels (Nicolosi et al., 1997). Unlike the results 
in rabbits and hamsters, the results from mice were somewhat 
conflicting (Arbones-Mainar et al., 2006; Munday et al., 1999; 
Nestel et al., 2006; Toomey et al., 2006). A mixture of CLA 
(9Z, 11E-CLA:10E, 12Z-CLA (80:20 blend)) was tested in 
ApoE-/- mice and showed a suppression of atherosclerotic lesions 
by decreasing pro- inflammatory genes (i.e., metalloproteinases 
(MMP)-9 and PECAM-1) and an increase in apoptotic genes 
(Toomey et al., 2006). Isomer-specificity of regulation of the 
lipid profile by CLA isomers was shown in a few studies. 
Mitchell et al. (2005) showed that 10E,12Z-CLA increased HDL 
levels in 1% CLA fed hamsters. However, Wilson et al. (2006) 
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10E,12Z-CLA increased cholesterol levels in 0.5% CLA isomer 
fed hamsters. This discrepancy may be due to the relative amount 
and composition of the CLA mix used in the studies. 
Different types of cell lines related to atherosclerosis were used 
to study the anti-atherogenic effects of CLA in in vitro systems. 
Decreased levels of 6-keto-prostaglandin F(1α) (6k-PGF(1α)), a 
stable breakdown product of PGI2, were observed in bovine aortic 
endothelial cells treated with CLA (Coen et al., 2004). CLA 
increased CD36 (scavenger receptor) in THP-1, human macrophages 
as well as reduced total lipids, PGE2, PGI2, and cytokine-induced 
NF-κB binding activity in human smooth muscle cells (Ringseis 
et al., 2006; Weldon et al., 2004). However, CLA failed to inhibit 
adhesion molecules which are important for the initiation step 
of atherosclerotic lesion formation, such as ICAM-1, VCAM-1, 
and E-selectin induced by TNF-α in human arotic EC (Schleser 
et al., 2006). Although there were no changes in ICAM-1 and 
VCAM-1 levels by CLA, CLA inhibited the adhesion activity 
of THP-1 cells to human umbilical vein EC (HUVEC) (Sneddon 
et al., 2006).
CLA’s fat-lowering effects have been reported in human 
subjects, although they have not been consistent. Benito et al. 
(2001) showed no alteration of cholesterol, TG, HDL, and LDL 
cholesterol levels in human on a 3.9 g/d CLA supplementation 
for 63 days. Desroches et al. (2005) reported that healthy subjects 
on CLA had lower total cholesterol, total cholesterol/HDL ratio 
compared to the subjects on control diet. On the other hand, 
Mougios  et al. (2001) and Gaullier et al. (2004) reported a 
detrimental HDL-lowering effect of CLA mix in humans. Tricon 
et al. (2004b) showed that 10E,12Z-CLA increased a ratio of 
cholesterol/HDL, LDL:HDL, and TG levels compared to 9Z,11E- 
CLA in healthy humans. In spite of isomer-specific effects of 
CLA on lipid profile, the same group reported a similar effect 
of those two CLA isomers on immune cell function as inhibiting 
mitogen-induced T cell activation (Tricon et al., 2004a). The 
CLA isomer-specificity varies depending on the results observed; 
therefore, studies on pure CLA isomers are needed to elucidate 
these questions. 
Some proposed mechanisms for the anti-atherogenic and lipid- 
lowering effects of CLA include roles for PPARs, sterol 
regulatory element-binding proteins (SREBPs) and stearoyl-CoA 
desaturase (SCD) (reviewed in (Bhattacharya et al., 2006)). 
Further studies using each CLA isomer and long-term clinical 
studies are needed to establish their potential anti-atherogenic 
effects and mechanism (s) of action.
9E,11E-CLA: its effects and mechanism
The isomer-specific effects of 9Z,11E-CLA and 10E,12Z-CLA 
are now well-recognized (reviewed in (Evans et al., 2002)). 
However, the less prevalent CLA isomers have not been intensively 
studied. Recently, more studies have reported the effects of 
9E,11E-CLA in colon cancer cells, endothelial cells, and macrophage 
cells (Beppu et al., 2006; Lai et al., 2005; Yasui et al., 2007). 
Lai et al. (2005) showed that among the CLA isomers, 9E,11E-CLA 
attenuated proliferation of bovine endothelial cells the most by 
enhancing caspase-3 activity. In the following year, Beppu et 
al. (2006) reported that 9E,11E-CLA showed the strongest 
apoptosis among 9Z,11Z-, 9Z,11E-, and 10E,12Z-CLA isomer on 
colon cancer cells, Caco-2 cells. The same researchers further 
reported the 9E,11E-CLA’s chemopreventive effect in rats fed 
0.1% or 1% 9E,11E-CLA for 4 wks (Yasui et al., 2007). Ecker 
et al. (2007) showed that 9E,11E-CLA, but not 9Z,11E- and 
10E,12Z-CLA, induces SREBP target genes such as ABCG-1 via 
a SREBP-1c-dependent mechanism in primary human monocyte- 
derived macrophages. Comparison of five different CLA isomers 
showed that 9E,11E-CLA indeed regulates gene expression distinctively 
different compared to the rest of CLA isomers in a mouse 
macrophage cell line, RAW 264.7 (Lee et al., 2008). Thus, isomer 
specificity of 9E,11E-CLA has been recognized in various cell types.
Although the portion of 9E,11E-CLA in American beef fat and 
commercial CLA mixtures ranged from 1.5-3.7% of the total 
CLA isomers (Kramer et al., 1998; Yurawecz, 1999), 9E,11E- 
and 9Z,11E-CLA were the main CLA isomers in serum isolated 
from women on 2.1 g of CLA supplementation for 45 days which 
represented 41% of the CLA total (Petridou et al., 2003). These 
isomers were also the two major CLA isomers in platelet lipids, 
17% and 33% of the total respectively (Al-Madaney et al., 2003). 
Based on the basal plasma CLA levels in healthy men as 7 μM, 
the 9E,11E-CLA concentration is estimated to be in the 1-3 μM 
range (Huang, 1994). Considering 10-fold higher concentration 
in local areas, 10-30 μM might be a physiologically relevant level 
of 9E,11E-CLA. Large-scale and economically efficient separation 
of 9E,11E-CLA is difficult due to its minimal existence in the 
CLA mixture. Kishino et al. (2002, 2003) reported the bacterial 
production of 9Z,11E- and 9E,11E-CLA from ricinoleic acid 
(12-hydroxy-cis-9-octadecaenoic acid) and linoleic acid. This 
biological system for 9E,11E-CLA production may promise the 
large-scale and selective preparation of 9E,11E-CLA.
Conclusion
In spite of intensive studies of CLAs performed over the last 
two decades, the mechanism of action of each CLA isomer is 
not well-appreciated yet. In this review, various health-related 
effects of CLAs were discussed with a focus on superior and/or 
distinctive characteristics of 9E,11E-CLA. The limited numbers 
of recent studies of 9E,11E-CLA in in vitro and in vivo studies 
suggest that this specific CLA isomer appears to have the 
anti-carcinogenic, anti-inflammatory, and potential anti-atherogenic 
effects. Although it requires more in vivo and clinical studies 
before making a solid conclusion, understanding the effects of 
the individual CLA isomer helps us to make a combination of 
the CLA isomers in dietary supplements to maximize its healthful 
effects and minimize its harmful effects. Yunkyoung Lee 329
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